Magic mushroom microdoses could lift Treatment-Resistant depression

NCT ID NCT07183748

Recruiting now Symptom relief Sponsor: Beersheva Mental Health Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether very small, repeated doses of psilocybin (the active ingredient in magic mushrooms) combined with talk therapy can safely reduce depression symptoms in people who haven't gotten better with standard treatments. Twenty adults aged 18-65 with treatment-resistant depression will receive either psilocybin or a placebo for six weeks, along with psychotherapy. Researchers will track mood, thinking skills, and biological markers like stress hormones.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: psilocybin
What this could lead to: If it works, this could point toward a new option for people with depression that hasn't responded to other treatments.
What could go wrong: This is a very small early-phase study with only 20 people. It may not show clear benefits, and participants must stop their usual medications, which carries risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TREATMENT RESISTANT DEPRESSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Depressive Disorder, Treatment-Resistant

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TREATMENT RESISTANT DEPRESSION

Contacts and locations

Locations

Mental Health Center Beer Sheva
RECRUITING

Beersheba, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.